Document is current
Any future updates will be listed below
-
Authors
Dias-Barbosa, Carla https://orcid.org/0000-0003-4701-8825
Igarashi, Hisaka
Duenas, Ashley
Hareendran, Asha
Kitamura, Shigekazu
Tanaka, Shigeya
Sanno, Naoko
Doi, Hikaru
Nagamitsu, Tsutomu
Tatsuoka, Yoshihisa
Matsumori, Yasuhiko
Hasebe, Miki
Takeshima, Takao
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03812224 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial
https://doi.org/10.1136/bmjopen-2022-068616
Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants
https://doi.org/10.1007/s40271-026-00813-6
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 14 December 2025
Accepted: 10 March 2026
First Online: 16 April 2026
Declarations
:
: C.D.-B., A.D., and A.H. contributed to conception and design of the study; analysis and interpretation of data for the manuscript; and drafting the manuscript. H.I., S.K., S.T., N.S., H.D., T.N., Y.T., Y.M., M.H., and T.T. contributed to acquisition and interpretation of data for the manuscript. All authors contributed to revising the manuscript critically for important intellectual content and approved the final version of the manuscript.
: C.D.-B. and A.D. are employees of PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, which was paid by Amgen to conduct the study and develop the manuscript. H.I. has received payments/honoraria for lectures/presentations/speaker bureaus/manuscript writing/educational events from Amgen, Daiichi Sankyo, Eisai, Eli Lilly, Otsuka Pharmaceutical, Pfizer, Sawai Pharmaceutical, and Sumitomo Pharma. A.H. is a former employee of PPD Evidera Patient-Centered Research, Thermo Fisher Scientific. S.K., N.S., and Y.M. have received honoraria for lectures from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka Pharmaceutical. S.T., H.D., T.N., and Y.T. have nothing to declare. M.H. is an employee of, and owns stock in, Amgen, which funded the study. T.T. has received consulting fees from Hedgehog MedTech, Sawai Pharmaceutical, and Teijin Pharma, and honoraria for lectures from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka Pharmaceutical.
: The trial protocol, including the qualitative interview substudy, was approved by the ethics committee (EC) or institutional review board (IRB) at each study site. Names of sites that recruited participants to the qualitative interview study and details of the corresponding ECs/IRBs are given in Table in the ESM. Please note that ECs and IRBs in Japan do not provide approval numbers. Informed consent was obtained from all trial participants. Additional informed consent was obtained from participants in the qualitative interview substudy prior to their participation.
: Qualified researchers may request study data from Amgen clinical studies. Further details are available from: .
